Term ends Oct 30, 2040 · High confidence
20-year base term ends Oct 30, 2040
Held by Regeneron Pharmaceuticals, Inc.
Filed Mar 7, 2024 as application 18/598,342 · Granted Jan 28, 2025
Base term, 20 years from filing
Today
2020
2040
Clock starts
Oct 30, 2020
Oct 30, 2020
Term ends
Oct 30, 2040
Oct 30, 2040
Granted
Jan 28, 2025
Jan 28, 2025
base term
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 12,570,756, to Oct 30, 2040. The term already ends on or before that date, so the cap shortened nothing.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 30, 2020, when application PCT/US2020/058373, the earliest non-provisional in its chain, was filed (this one was filed Mar 7, 2024) | Oct 30, 2040 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 12,570,756) | resolves to Oct 30, 2040, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 30, 2040 | High confidence |
This family
| Application PCT/US2020/058373 | PCT application no patent term | no patent term |
| US 12,570,756 | In force Dec 2042 | Dec 2042 |
| US 12,209,135 | this patent Oct 2040 | Oct 2040 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 21, 2024 Reel 68359, frame 531 | Widboom, Paul Fredrick; Cruite, Patricia Ann | Adimab, LLC | Assignment of Assignor's Interest |
| Aug 21, 2024 Reel 68359, frame 603 | Adimab, LLC | Magenta Therapeutics, Inc. | Assignment of Assignor's Interest |
| Aug 21, 2024 Reel 68359, frame 742 | Panwar, Rajiv | Magenta Therapeutics, Inc. | Assignment of Assignor's Interest |
| Aug 21, 2024 Reel 68359, frame 880 | Magenta Therapeutics, Inc. | Vor Biopharma Inc. | Assignment of Assignor's Interest |
| Aug 21, 2024 Reel 68685, frame 223 | Boitano, Anthony; Cooke, Michael; McDonagh, Charlotte; Palchaudhuri, Rahul; Pearse, Bradley R. | Magenta Therapeutics, Inc. | Assignment of Assignor's Interest |
| Dec 22, 2025 Reel 74028, frame 972 | Vor Biopharma, Inc. | Regeneron Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 16, 2026 Reel 73495, frame 746 | Vor Biopharma, Inc. | Regeneron Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Oct 2040
Term ends Oct 30, 2040. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 12,570,756, ends no earlier than this term, so it caps nothing.
Citations
0
later US patents cite this one
Fewer than half of the utility patents granted in 2025 in our data have been cited yet, so we show the count and do not rank on it.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.